Items where authors include "Lindsay, J"

Article

Croft, J, Ellis, S, Sherborne, AL et al. (19 more authors) (2021) Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia, 35 (7). pp. 2043-2053. ISSN 0887-6924

Jackson, GH, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (21 more authors) (2021) Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. British Journal of Haematology, 192 (5). bjh.16945. pp. 853-868. ISSN 0007-1048

Jackson, GH, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (21 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277

Glasbey, JC, Nepogodiev, D, Omar, O et al. (3453 more authors) (2020) Delaying surgery for patients with a previous SARS-CoV-2 infection. British Journal of Surgery, 107 (12). e601-e602. ISSN 0007-1323

Jackson, GH, Davies, FE, Pawlyn, C et al. (20 more authors) (2020) Lenalidomide Before And After ASCT For Transplant-Eligible Patients Of All Ages In The Randomized, Phase III, Myeloma XI Trial. Haematologica. haematol.2020.247130. ISSN 0390-6078

Jackson, GH, Davies, FE, Pawlyn, C et al. (19 more authors) (2019) Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 6 (12). e616-e629. ISSN 2352-3026

Jackson, GH, Davies, FE, Pawlyn, C et al. (19 more authors) (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 20 (1). pp. 57-73. ISSN 1470-2045

Jones, JR, Cairns, DA, Gregory, WM orcid.org/0000-0003-2641-8416 et al. (19 more authors) (2016) Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer Journal, 6 (12). e506. ISSN 2044-5385

Proceedings Paper

Bygrave, CA, Pawlyn, C, Davies, FE et al. (19 more authors) (2018) Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .

Jackson, GH, Davies, FE, Pawlyn, C et al. (18 more authors) (2018) A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San DIego, California, USA. American Society of Hematology , p. 302.